EGFR and lung carcinoma: An in vitro study performed by Cheng H et al [20] investigating differential effects of various sequences of paclitaxel with gefitinib on lung cancer cell lines with activating EGFR mutation, revealed that the sequence of paclitaxel followed by gefitinib arrested cells in G1, whereas the reverse sequence arrested cells in S and G2 phases.